|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2,405.15 INR | -0.76% |
|
-4.62% | -2.66% |
| 01:07pm | GlaxoSmithKline Pharmaceuticals Ltd says Juby Chandy resigns as whole-time director and CFO | RE |
| 03-02 | GlaxoSmithKline Pharmaceuticals Names CFO | MT |
| Capitalization | 407B 4.41B 3.85B 3.48B 3.33B 6.05B 6.29B 41.56B 16.47B 195B 16.53B 16.18B 703B | P/E ratio 2026 * |
39.4x | P/E ratio 2027 * | 35.1x |
|---|---|---|---|---|---|
| Enterprise value | 407B 4.41B 3.85B 3.48B 3.33B 6.05B 6.29B 41.56B 16.47B 195B 16.53B 16.18B 703B | EV / Sales 2026 * |
10.5x | EV / Sales 2027 * | 9.53x |
| Free-Float |
24.42% | Yield 2026 * |
1.23% | Yield 2027 * | 1.23% |
Last Transcript: GlaxoSmithKline Pharmaceuticals Limited
| 1 day | -0.76% | ||
| 1 week | -4.62% | ||
| Current month | -6.41% | ||
| 1 month | -7.44% | ||
| 3 months | -7.08% | ||
| 6 months | -12.17% | ||
| Current year | -2.66% |
| 1 week | 2,379 |  | 2,555 |
| 1 month | 2,379 | | 2,693.65 |
| Current year | 2,220 | | 2,715.15 |
| 1 year | 2,220 | | 3,515.95 |
| 3 years | 1,228 | | 3,515.95 |
| 5 years | 1,228 | | 3,515.95 |
| 10 years | 1,020 | | 3,515.95 |
| Manager | Title | Age | Since |
|---|---|---|---|
Bhushan Akshikar
CEO | Chief Executive Officer | 56 | 30/11/2022 |
Juby Chandy
DFI | Director of Finance/CFO | - | 31/03/2022 |
Shalini Menon
CTO | Chief Tech/Sci/R&D Officer | - | 07/07/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
Subesh Williams
BRD | Director/Board Member | 64 | 06/04/2017 |
Renu Sud Karnad
CHM | Chairman | 73 | 31/03/2019 |
| Director/Board Member | 59 | 17/05/2020 |
| Name | Varia. Jan 1. | Weight | AuM | |
|---|---|---|---|---|
 | +1.43% | 0% | 32 M€ |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -0.76% | -4.62% | -10.67% | +90.83% | 4.44B | |
| -0.55% | -2.47% | +19.24% | +198.44% | 880B | |
| +0.60% | +0.37% | +49.52% | +58.07% | 582B | |
| +0.36% | -2.43% | +3.48% | +42.90% | 388B | |
| +0.56% | -3.07% | +3.57% | +23.31% | 324B | |
| +0.13% | -0.22% | +21.05% | +33.45% | 295B | |
| +0.43% | -2.65% | +23.71% | +58.44% | 293B | |
| +0.34% | -1.65% | +21.51% | +7.30% | 286B | |
| +0.12% | -2.31% | +16.11% | +56.99% | 197B | |
| -0.26% | -1.18% | +29.08% | +81.47% | 180B | |
| Average | +0.13% | -1.68% | +17.66% | +65.12% | 343.06B | |
| Weighted average by Cap. | +0.15% | -1.37% | +22.13% | +83.97% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 38.91B 421M 368M 332M 318M 578M 601M 3.97B 1.57B 18.59B 1.58B 1.55B 67.14B | 42.76B 462M 404M 365M 349M 635M 660M 4.36B 1.73B 20.43B 1.73B 1.7B 73.79B |
| Net income | 10.43B 113M 98.61M 89.09M 85.22M 155M 161M 1.06B 422M 4.99B 423M 414M 18.01B | 11.61B 126M 110M 99.14M 94.84M 172M 179M 1.18B 469M 5.55B 471M 461M 20.04B |
| Net Debt | - | - |
Employees
3,113
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|---|---|---|
| 16/03/26 | 2,405.15 ₹ | -0.76% | 1,431 |
| 13/03/26 | 2,423.55 ₹ | -3.22% | 2,721 |
| 12/03/26 | 2,504.15 ₹ | +0.76% | 6,323 |
| 11/03/26 | 2,485.15 ₹ | -0.26% | 3,187 |
| 10/03/26 | 2,491.55 ₹ | -1.20% | 3,084 |
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
2,423.55INR
Average target price
3,064.50INR
Spread / Average Target
+26.45%
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- GLAXO Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition